Arvind Kush Biography and Net Worth

Arvind Kush, the Chief Financial and Chief Business Officer of Candid Therapeutics, has over 15 years of finance and investment banking experience. Prior to Candid, Arvind was Chief Financial Officer at RayzeBio, where he helped the company raise over $160 million in a private financing in 2022, complete its $350+ million IPO in 2023 and close its $4.1B acquisition Bristol Meyers Squibb in February 2024. Arvind holds a Bachelor in Engineering in Computer Science from Visvesvaraya Technological University and an MBA from Goizueta Business School, Emory University.

What is Arvind Kush's net worth?: The estimated net worth of Arvind Kush is at least $270.43 thousand as of October 21st, 2024. Kush owns 145,000 shares of Inhibikase Therapeutics stock worth more than $270,425 as of June 23rd. This net worth evaluation does not reflect any other assets that Kush may own. Learn More about Arvind Kush's net worth.
How do I contact Arvind Kush?: The corporate mailing address for Kush and other Inhibikase Therapeutics executives is 3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA, GA, 30339. Inhibikase Therapeutics can also be reached via phone at (678) 392-3419 and via email at [email protected]. Learn More on Arvind Kush's contact information.
Has Arvind Kush been buying or selling shares of Inhibikase Therapeutics?: Arvind Kush has not been actively trading shares of Inhibikase Therapeutics over the course of the past ninety days. Most recently, on Monday, October 21st, Arvind Kush bought 145,000 shares of Inhibikase Therapeutics stock. The stock was acquired at an average cost of $1.37 per share, with a total value of $198,650.00. Following the completion of the transaction, the director now directly owns 145,000 shares of the company's stock, valued at $198,650. Learn More on Arvind Kush's trading history.
Who are Inhibikase Therapeutics' active insiders?: Inhibikase Therapeutics' insider roster includes Arvind Kush (Director), and Milton Werner (CEO). Learn More on Inhibikase Therapeutics' active insiders.

Arvind Kush Insider Trading History at Inhibikase Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/21/2024	Buy	145,000	$1.37	$198,650.00	145,000

Arvind Kush Buying and Selling Activity at Inhibikase Therapeutics

Inhibikase Therapeutics Company Overview

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Today's Range

Now: $1.87

$1.81

$1.89

50 Day Range

MA: $1.77

$1.57

$2.06

2 Week Range

Now: $1.87

$1.33

$2.26

Volume

543,921 shs

Average Volume

1,338,293 shs

Market Capitalization

$246.90 million

P/E Ratio

N/A

Dividend Yield